Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

• Lenacapavir (Drug), also known as LEN: Administered subcutaneously
• Lenacapavir Tablet (Drug), also known as LEN: Administered orally
• Teropavimab (Drug), also known as TAB, GS-5423: Administered intravenously (IV)
• Zinlirvimab (Drug), also known as ZAB, GS-2872: Administered IV
• Cabotegravir (Drug), also known as CAB: Administered intramuscular (IM)
• Rilpivirine (Drug), also known as RPV: Administered IM

Primary outcomes

• Proportion of Participants With HIV-1 ribonucleic acid (RNA) ≥ 50 Copies/mL at Week 52 as Defined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm. [Week 52]

Secondary outcomes

• Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 92 as Defined by the US FDA Snapshot Algorithm. [Week 92]
• Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot Algorithm [Week 52]
• Proportion of Participants with HIV-1 RNA < 50 copies/mL at Week 92 as Determined by the US FDA Snapshot Algorithm. [Week 92]
• Change From Baseline in clusters of differentiation 4 (CD4) (CD4)+ T-cell Counts at Week 52 [Baseline, Week 52]
• Change From Baseline in CD4+ T-cell Counts at Week 92 [Baseline, Week 92]
• Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) [Up to Week 92]
• Percentages of Participants Prematurely Discontinuing Their Study Treatment due to an AE [Up to Week 92]
• Trough Concentrations for LEN, TAB, and ZAB at Week 26 [Week 26]
• Trough Concentrations for LEN, TAB, and ZAB at Week 52 [Week 52]
• Trough Concentrations for LEN, TAB, and ZAB at Week 104 [Week 104]
• Percentages of Participants With Antidrug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) of TAB [Up to 92 Weeks]
• Percentages of Participants With of ADAs and NAbs of ZAB [Up to 92 Weeks]

Sex: All, ages: 18 Years to any

Key Inclusion Criteria:

* Human immunodeficiency virus type 1 (HIV-1) susceptibility results from screening meeting specific criteria:

  1\) Proviral phenotypic susceptibility to both TAB and ZAB by the investigational protocol-defined assay at screening.
* At least 1 documented HIV-1 RNA level measured between 6 months and 12 months (+2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL). A single virologic elevation of ≥ 50 copies/mL and < 400 copies/mL (transient detectable viremia or "blips") prior to screening are acceptable if the subsequent plasma HIV-1 RNA level is < 50 copies/mL.
* A plasma HIV-1 RNA test < 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL) within the last 6 months prior to screening.

  1\) If > 1 plasma HIV-1 RNA measurements in the last 6 months prior to screening are available, all must be < 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).
* On a stable oral ARV therapy (ART) for ≥ 6 months prior to screening.

  1. A change in ART regimen ≥ 3 months prior to the screening visit for reasons other than virologic failure (VF) (eg, tolerability, simplification, drug-drug interaction profile) is allowed; individuals with a change in ART regimen ≥ 3 months prior to screening must have been on the regimen for ≥ 3 months prior to screening, and all HIV-1 RNA measurements in that period must be < 50 copies/mL. There are no permitted changes to ART regimens between screening and Day 1.

Key Exclusion Criteria:

* History of an opportunistic infection or illness indicative of Stage 3 HIV disease.
* History of treatment failure.
* Known or suspected resistance to either CAB or RPV.

  1. Resistance to CAB defined as the following mutations: G118R, Q148K, Q148R, T66K+L74M, E92Q+N155H, E138A+Q148R, E138K+Q148K/R, G140C+Q148R, G140S+Q148H/K/R, Y143H+N155H, and Q148R+N155H.
  2. Resistance to RPV defined as the following mutations: K101E and P; E138A, G, K, R, and Q; V179L; Y181C, I, and V; Y188L; H221Y; F227C; M230I and L, and the combination of L100I/K103N.
* Individuals with a dermatologic condition or implanted prothesis overlying the gluteal injection site for CAB + RPV.
* Known hypersensitivity to the study intervention, its metabolites, or formulation excipients.
* Active, serious infections (other than HIV-1) requiring therapy < 30 days prior to randomization.
* Active tuberculosis infection.
* Acute hepatitis of any cause < 30 days before randomization.
* History of, or current clinical decompensated liver cirrhosis (eg, ascites, encephalopathy, or variceal bleeding) or severe hepatic impairment (Child-Pugh Class C).
* Active malignancy requiring acute systemic therapy.
* Have poor venous access that would limit phlebotomy or intravenous (IV) infusion of study drugs.
* Prior use of, or exposure to, LEN or a broadly neutralizing antibody (bNAb) for HIV-1.
* Prior use of, or exposure to, long-acting (LA) injectable CAB or LA injectable RPV.
* Prior use of, or exposure to, ibalizumab, fostemsavir, or maraviroc.
* Baseline regimen consisting of monotherapy with any single antiretroviral (ARV).
* Treatment with immunosuppressant therapies (eg, corticosteroids, immunoglobulins, and other immune- or cytokine-based therapies) within 4 weeks of screening (with the exception of a single short course of corticosteroids lasting ≤ 7 days) or have a comorbid condition with an anticipated need ongoing immunosuppressive treatment during the study.
* Hepatitis C virus (HCV) antibody positive and HCV RNA detectable.
* Chronic hepatitis B virus (HBV) infection, as determined by either:

  1. Positive HBV surface antigen and negative HBV surface antibody, regardless of HBV core antibody status, at the screening visit.
  2. Positive HBV core antibody and negative HBV surface antibody, regardless of HBV surface antigen status, at the screening visit.
* Severe renal impairment-estimated glomerular filtration rate < 30 mL/min according to the Cockcroft-Gault formula.
* Abnormal electrocardiogram (ECG) at the screening visit that is clinically significant, as determined by the investigator.
* Any of the following laboratory values at screening:

  1. Alanine aminotransferase > 5 x upper limit of normal (ULN).
  2. Direct bilirubin > 1.5 x ULN.
  3. Platelets < 50,000/mm\^3.
  4. Hemoglobin < 8.0 g/dL.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

• Gilead Study Director, Study director, Gilead Sciences

NIH grants: 2025